Your session is about to expire
← Back to Search
Radiation Therapy
1 for Amyotrophic Lateral Sclerosis
Phase 1
Waitlist Available
Led By Ken Nedd, M.D.
Research Sponsored by GAAD Medical Research Institute Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
* Patients with ALS
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
Amyotrophic Lateral Sclerosis (ALS, sometimes called Lou Gehrig's s Disease, or Maladie de Charcot) is a progressive, usually fatal, neurodegenerative disease caused by the degeneration of motor neurons, the nerve cells in the central nervous system that control voluntary muscle movement. This study will investigate the use of far infrared radiation for the control, management and treatment of ALS.
Eligible Conditions
- Amyotrophic Lateral Sclerosis
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment2 Interventions
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Far infrared radiation
2019
N/A
~210
Find a Location
Who is running the clinical trial?
GAAD Medical Research Institute Inc.Lead Sponsor
21 Previous Clinical Trials
88 Total Patients Enrolled
Ken Nedd, M.D.Principal InvestigatorGAAD Medical Research Institute Inc.
19 Previous Clinical Trials
86 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger